GNAS mutations suppress cell invasion by activating MEG3 in growth hormone–secreting pituitary adenoma

Approximately 30%–40% of growth hormone–secreting pituitary adenomas (GHPAs) harbor somatic activating mutations in GNAS (α subunit of stimulatory G protein). Mutations in GNAS are associated with clinical features of smaller and less invasive tumors. However, the role of GNAS mutations in the invasiveness of GHPAs is unclear. GNAS mutations were detected in GHPAs using a standard polymerase chain reaction (PCR) sequencing procedure. The expression of mutation-associated maternally expressed gene 3 (MEG3) was evaluated with RT-qPCR. MEG3 was manipulated in GH3 cells using a lentiviral expression system. Cell invasion ability was measured using a Transwell assay, and epithelial–mesenchymal transition (EMT)-associated proteins were quantified by immunofluorescence and western blotting. Finally, a tumor cell xenograft mouse model was used to verify the effect of MEG3 on tumor growth and invasiveness. The invasiveness of GHPAs was significantly decreased in mice with mutated GNAS compared with that in mice with wild-type GNAS. Consistently, the invasiveness of mutant GNAS-expressing GH3 cells decreased. MEG3 is uniquely expressed at high levels in GHPAs harboring mutated GNAS. Accordingly, MEG3 upregulation inhibited tumor cell invasion, and conversely, MEG3 downregulation increased tumor cell invasion. Mechanistically, GNAS mutations inhibit EMT in GHPAs. MEG3 in mutated GNAS cells prevented cell invasion through the inactivation of the Wnt/β-catenin signaling pathway, which was further validated in vivo. Our data suggest that GNAS mutations may suppress cell invasion in GHPAs by regulating EMT through the activation of the MEG3/Wnt/β-catenin signaling pathway.


Introduction
Growth hormone-secreting pituitary adenoma (GHPA) accounts for 12.5% of pituitary neuroendocrine tumors, and excessive growth hormone results in acromegaly and systemic complications [1].Acromegaly has been associated with a two-fold increase in mortality, mainly due to cardiovascular disease, which can be reversed by treatments for controlling hormone overproduction [2].Approximately one-half of the patients with GHPA experienced high-risk relapse following surgical reduction owing to tumor cell infiltration of the surrounding tissues [3].Thus, supplementary chemotherapy is warranted to control tumor recurrence.
The genome-wide analysis of epigenetic changes revealed specific subgroup molecular characteristics of pituitary adenoma [4].For example, the hypomethylation of GH1 and SST5 promoters is associated with the overexpression of the respective genes in GHPAs, and POMC is hypomethylated in corticotroph adenomas.The somatic mutations of GNAS and USP8 combined with transcriptome analysis have been identified in GHPAs and corticotroph adenomas.
Mutations in GNAS, which encodes the α subunit of the stimulatory G protein, were detected in ~40% GHPAs [5,6].Functional studies have suggested that GNAS mutations constitutively activate adenylyl cyclase (AC), thereby inducing the cyclic AMP (cAMP) signaling pathway in pituitary tumors [7].Studies have reported that somatostatin and its analogs reduce GH secretion through multiple mechanisms involving AC inhibition [8].Somatostatin binding sites are negatively coupled to AC; however, the inhibition of hormone secretion by somatostatin cannot be explained solely through AC inhibition [8].It has been speculated that somatostatin blocks basal hormone release by a mechanism different from that of the inhibition of cAMP formation.In addition, it has been suggested that the volume of GNAS-mutant GHPA is smaller and it is less likely to be invasive [9].
Maternally expressed gene 3 (MEG3), a large non-coding RNA (lncRNA), was first identified as a tumor suppressor in the pituitary [10].Our previous study suggested that MEG3 expression is associated with GNAS mutations and it is involved in regulation of growth hormone hypersecretion, proliferation, and invasiveness of GHPAs [11].The cAMP response element (CRE), located in the MEG3 proximal promoter region, is critical for MEG3 expression [12].Cyclic adenosine monophosphate-responsive element-binding protein, as a downstream target of mutated GNAS, is also implicated in the upregulation of MEG3 by binding to the CRE site [12,13].Some studies have suggested that MEG3 suppresses tumor cell proliferation and invasion by downregulating related proteins [14,15].The Wnt/β-catenin pathway plays an important role in tumorigenesis, cellular proliferation, and invasion [16].Extensive studies have shown that lncRNAs have the potential to target canonical Wnt-related components during epithelial-mesenchymal transition (EMT) process [17].Studies have demonstrated that MEG3 negatively regulates the Wnt/β-catenin signaling pathway in tumor growth and invasion [18,19].Recently, MEG3 was shown to induce the phosphorylation, ubiquitination, and degradation of β-catenin through GSK-3β, which in turn inactivates the Wnt pathway and ultimately inhibits the invasion and metastasis of retinoblastoma cells [20].This study aimed to ascertain whether mutations in GNAS inhibit the invasiveness of GHPA cells mainly through MEG3-mediated inactivation of the Wnt/β-catenin pathway.The findings of this study may provide a new therapeutic approach for treating GHPA.

Patients and clinical characteristics
Tumor samples were collected from 44 patients (21 men and 23 women) with acromegaly who underwent endoscopic endonasal transsphenoidal surgery at the Department of Neurosurgery of Nanjing Jinling Hospital (Nanjing, China) between November 2018 and November 2019.The inclusion criteria were as follows: (i) available results of biochemical tests and magnetic resonance images (MRIs) before any treatment, (ii) pituitary adenomas that can be identified via radiological study, and (iii) histological diagnosis of GHPAs by pathologists in Nanjing Jinling Hospital.The exclusion criteria were as follows: (i) patients who have undergone radiotherapy and drug therapy before surgery and (ii) patients with residual or recurrent tumor following surgery.Overall, 10 patients with clinically nonfunctioning pituitary adenoma (NFPA) were included as negative controls.Approval for the study was obtained from the Ethical Committee of Nanjing Jinling Hospital (2018NZKY-008-02) and informed consent were obtained from all patients who participated in this study.This study was performed according to the ethical standards of the 1964 Helsinki Declaration.Pituitary adenomas were classified into invasive and noninvasive tumors according to the degree of lateral extension to the cavernous sinus space via MRI scanning [21].Knosp grades 3 and 4 were defined as invasive pituitary adenomas, and Knosp grades 0-2 were defined as noninvasive tumors [22].Tumor volume was determined using the formula (length × width × height × Π)/6.The clinical characteristics of the patients are described in Table 1.

Detection of mutations in GNAS
Genomic DNA was extracted from 44 GHPA and 10 NFPA tissues using a DNA miniprep kit, according to the manufacturer's protocol (Qiagen GmbH, Hilden, Germany).Point mutations in GNAS reported in tumor specimens included the CGT-to-TGT mutation at codon 201 (Arg201Cys) and the CAG-to-CTG mutation at codon 227 (Gln227Leu) [23].PCR amplification of codons 201 and 227 was performed using Taq DNA-Polymerase (TTH Biotools Madrid, Spain) [23].The PCR products were purified using a PCR purification kit (Qiagen GmbH, Hilden, Germany) and sequenced using an ABI3730XL analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Carlsbad, CA, USA).Primer sequences used for PCR and DNA sequencing are listed in Table 2.

Cell culture and transduction
The GH3 cell line (rat GH-secreting pituitary tumor cell line), which produces both growth hormone and prolactin, was A pWPT lentiviral expression vector (Genechem, Shanghai, China) was used to clone wild-type and mutant GNAS, and the generated constructs were termed pWPT-GNAS (expressing GNAS wild-type), pWPT-GNAS-Q227L (expressing GNAS mutated at Q227L), and pWPT-GNAS-R201C (expressing GNAS mutated at R201C).GH3 cells were plated in 6-well plates at 70% confluence and then injected with lentivirus to express wild-type or mutant-type GNAS.Overexpressed or knocked-down MEG3 gene was packaged by lentivirus and then transfected into GH3 cells according to the protocols (Corues Biotechnology, Nanjing, China).
RNA extraction and quantitative reverse transcription real-time quantitative PCR Total RNA was isolated from tissues or cells using Trizol reagent and reverse transcribed into complementary DNA using the TaqMan MicroRNA Reverse Transcription Kit (TaKaRa, Dalian, China).Real-time quantitative (RT-q) PCR was performed using SYBR Green PCR Master Mix (Takara, Japan) according to the manufacturer's instructions.The sequences of qPCR primers are listed in Table 2.
lncRNA MEG3 was normalized with β-actin and the level of MEG3 in GHPA was further normalized with its level in NFPA.The experiments were repeated at least three times.

RNA-Seq analysis
Total RNA from GH3 cells with MEG3-overexpressed and MEG3-overexpress-vector was extracted using Trizol reagent (Thermo Fisher, Waltham, USA) according to the manufacturer's protocol.RNA samples were digested with RNase free DNase I (Invitrogen, Carlsbad, USA) to eliminate residual genomic DNA, and the digestion products were purified using magnetic beads (Axygen, Union City, USA).
Total RNA was qualified by Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).The next-generation sequencing library was prepared according to the protocol provided by the manufacturer (NEBNext Ultra RNA Library Prep Kit for Illumina HiSeq system).The sequences and data were analyzed to identify differentially expressed genes (Genewiz, Shanghai, China).

Transwell assay
Matrigel matrix diluent (300 μg/mL) was used to coat the bottom of the upper chamber of the Transwell chamber in a precooled environment at 4 C.The volume ratio of serumfree F12 medium to Matrigel in the upper chamber was 4:1, the total volume was 100 μL, and the Matrigel was frozen overnight at 4 C.The next day, 500 μL of F12 medium containing 10% FBS was added into the lower chamber.Cells (1 × 10 5 ) were seeded in the upper chamber.After incubation for 48 h, non-invading cells in the upper chamber were removed.Cells that invaded the bottom chamber were fixed with 4% paraformaldehyde and stained using 0.1% crystal violet (Beyotime Biotech., Shanghai, China).Five random fields were selected for counting under a microscope (magnification, ×200).Each experiment was performed three times.

Immunofluorescence
Tumor tissue sections were prepared from the surgical resection of GHPA.Tissue slides were fixed with 4% formaldehyde, blocked with 10% normal goat serum, and incubated overnight at 4 C with primary antibodies against β-catenin, E-cadherin, N-cadherin, and vimentin (diluted at 1:100 in PBS).All antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA).The slides were removed from the incubation chamber, washed three times with PBST, and incubated for 40 min in the dark in a humidified chamber at room temperature with goat polyclonal secondary antibodies against rabbit IgG (1:300; Abcam Biotechnology, Cambridge, MA, USA) reconstituted in PBS.Sections were washed three times with PBST.After counterstaining was complete, the sections were treated with glycerol/PBS (2:1) for 10 min in the dark at room temperature.Five randomly chosen fields were selected for counting using an Axiovert 200 fluorescent microscope.

Subcutaneous xenografts in nude mice
Animal experiments were approved by the Animal Experimentation Ethics Committee of the Jinling Hospital of Nanjing University (protocol number: 2021DZGKJ DWSL-0081).Four-week-old female athymic BALB/c nude mice were purchased from the Shanghai SLAC Laboratory Animal Co., Ltd.(Shanghai, China) and housed and maintained in laminar airflow chambers under specific pathogen-free conditions.MEG3-overexpressing GH3 cells (10 7 cells/0.1 mL) were subcutaneously injected into the right back side of the mice.Following the tumor formation, a week after injection, lithium chloride (Sigma-Aldrich, St. Louis, MO, USA; 60 mg/kg/d in 100 μL saline), a β-catenin activator, was administered daily via intraperitoneal injection in the group with high levels of MEG3.The other groups were injected with saline alone as controls.Tumor volumes were measured using a vernier caliper twice a week and calculated as (length × width 2 )/2.Four weeks after the injection, the mice were euthanized via cervical dislocation, and the dissected tumors were weighed and processed to determine the expression levels of related proteins, including β-catenin, E-cadherin, Ncadherin, MMP-2, and MMP-9.

Statistical analysis
Data were statistically analyzed using SPSS 19.0.Student's unpaired t-test and Fisher's exact test were used for intergroup analysis.One-way analysis of variance test was used to compare tumor volume and weight among the three groups of in vivo experiments when the mice were euthanized.The results are presented as mean ± standard deviation.Correlation was analyzed using Spearman's correlation.p < 0.05 was considered statistically significant.

GNAS mutations in GHPA
In total, 44 patients with GHPA and 10 patients with NFPA were enrolled in this study.Mutations in GNAS were scanned by directly sequencing genomic PCR products amplified from the tumor samples of patients using specific primer sets.The results revealed that 16/44 patients carried GNAS mutations, including 8 cases of codons 227 and 201 each.Conversely, no GNAS mutation was detected in the 10 patients with NFPA.Subsequently, the patients were divided into two groups (GNAS-WT, n = 28; GNAS-MUT, n = 16).The percentage of invasive tumors (Knosp grades 3 and 4) in GNAS-MUT tumors remarkably decreased (18.7% vs. 71.4%;p = 0.001; Table 1).There were no statistical differences in terms of age or gender between the two groups.

Mutant GNAS upregulates MEG3 expression
Because GNAS mutations are speculated to participate in upregulating MEG3 expression, the expression levels of MEG3 in NFPA and GHPA tumor tissues were quantified via RT-qPCR.The levels of MEG3 considerably increased in 44 GHPA tumor tissues compared with the 10 NFPA tumor tissues (p = 0.0003) (Fig. 2A).Intriguingly, MEG3 expression further increased in the 16 GHPA tumor tissues with mutant GNAS compared with the 28 wild-type tumors (p = 0.006; Fig. 2B).Consistently, the high levels of MEG3 were verified in GHPA tumor tissues with single mutant sites at Q227L and R201C (4.7-fold, p = 0.0004; 4.4-fold, p = 0.0033; Fig. 2C).Importantly, tumor invasiveness significantly declined in the group expressing high levels of MEG3 compared with the group expressing low levels of MEG3 (p = 0.0014; Fig. 2D).We suggest that MEG3 negatively correlates with tumor invasion in GHPA.

MEG3 inhibits cell invasion by inactivating the Wnt/β-catenin signaling pathway
To investigate the mechanism by which MEG3 inhibits GHPA cell invasion, MEG3 was overexpressed in GH3 cells and the RNA expression profile was analyzed by RNA-Seq.The results revealed that the Wnt/β-catenin signaling pathway could be involved in regulating cell invasion (Fig. 4A).Consistently, the mRNA level of β-catenin significantly decreased in GH3 cells with GNAS mutations (GH3-Q227L: p = 0.0047, GH3-R201C: p = 0.005) (Fig. 4B).Ectopic expression of MEG3 in GH3 cells resulted in reduced βcatenin expression (p < 0.01); conversely, silencing of MEG3 in GH3 cells increased the levels of β-catenin (p < 0.05) (Fig. 4B and C).Significant negative relationships were found between the expression levels of MEG3 and β-catenin (p < 0.05) (Fig. 4D).Consistently, the level of β-catenin in GHPA-carrying GNAS mutations (n = 16) was lower than that in wild-type tumors (n = 28) (p = 0.001), which are associated with high levels of MEG3 (Fig. 4E).The results suggest that MEG3 negatively regulates β-catenin and promotes cell invasion, particularly in GHPA cells carrying GNAS mutations.

GNAS mutations inhibit EMT
EMT plays a fundamental role in promoting cell mobility and tumor metastasis, and Wnt/β-catenin signaling is a key mechanism in EMT [28,29].To examine the effects of GNAS mutations on EMT, we quantified the expression of EMTassociated proteins regulated by β-catenin, such as Ecadherin (cell adhesion marker), as well as N-cadherin and vimentin (mesenchymal markers), using immunofluorescence in GHPA tissues.Compared with GHPA tissue with wildtype GNAS, GHPA tissue with GNAS mutations exhibited increased E-cadherin (p < 0.0001), decreased N-cadherin (p < 0.01) and vimentin (p < 0.05), and high constitutive levels of MEG3 (Figs. 6A and 6B).Thus, our findings suggest that GNAS mutations inhibit the invasiveness of GHPA by downregulating EMT (Fig. 6C).

In vivo validation of MEG3-mediated inhibition of cell invasion
To further verify that MEG3 suppresses cell invasion in GHPA by inhibiting β-catenin-regulated EMT, β-catenin was manipulated by overexpressing MEG3 in GH3 cells.The cells were subcutaneously injected into nude mice for tumor formation (Fig. 7A).The sustained efficiency of MEG3 upregulation was verified by detecting the expression level of MEG3 in the xenograft tumor of each mouse via RT-qPCR.Notably, MEG3 level increased >four-fold in the MEG3-overexpressing group compared with the MEG3-oevt group and was unaffected by LiCl (Fig. 7B).Consistent with the regulated levels of β-catenin in the formed tumors, E-cadherin increased upon overexpressing MEG3 and further decreased following LiCl treatment.Conversely, the expression levels of N-cadherin, β-catenin, MMP-2, and MMP-9 decreased by elevating MEG3 and increased via LiCl-mediated induction (Figs.7C and 7D).The results confirmed that MEG3 negatively regulates EMT by downregulating β-catenin.

Discussion
GHPA is a typically benign tumor with a high incidence and large economic burden and often manifests with invasive growth [30].Numerous studies have indicated that the presence of point mutations in GNAS strongly reflects the biological characteristics of GHPAs, such as tendency for densely granulated tumors and smaller tumor size [31][32][33].A meta-analysis has suggested that GNAS mutations can be used as a prognostic factor for treatment response to  were quantified via immunofluorescence assay and confirmed via RT-qPCR (magnification, ×200).B: Cell invasion was analyzed using the Transwell assay (magnification, ×200).C: Expression levels of MMP-2 and MMP-9 in MEG3-overexpressing cells were measured via western blotting.D: Cell invasion of MEG3 knockdown in GH3 cells expressing mutant GNAS was detected using the Transwell assay (magnification, ×200).E: Expression levels of MMP-2 and MMP-9 of MEG3 knockdown in GH3 cells expressing mutant GNAS were measured via western blotting.*p < 0.05, **p < 0.01, and ***p < 0.001 show the statistical significance between the two groups as indicated, and "ns" shows no significance.MEG3-oe-vt: GH3 cells expressing empty vector of overexpressed MEG3; MEG3-oe: GH3 cells expressing overexpressed MEG3; MEG3-si-vt: GH3 cells containing MEG3 siRNA expressing empty vector; MEG3-si: GH3 cells containing MEG3 siRNA expressing vector.
somatostatin analogs [34].A study has suggested that Gsα protein encoded by GNAS is important for activating the cAMP-dependent pathway in pituitary cells for differentiation and proliferation [35].GNAS mutations were proposed to be involved in the constitutive activation of cAMP, which plays a causal role in pituitary adenomas [36].However, the poor growth rate of GHPAs naturally expressing GNAS mutations strongly suggest counteraction of the putative growth advantage conferred by cAMP.Consequently, this study aimed to elucidate the effect of FIGURE 4. MEG3 inhibits the invasiveness of GHPA with GNAS mutations by inactivating Wnt/β-catenin signaling.A: RNA-Seq was used to examine the gene expression profiles in MEG3-overexpressed GH3 cells compared with vector-only controls.The altered mRNA expression profile was analyzed using Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis.B: Reduction of β-catenin mRNA expression in GHPA tumors with the GNAS mutations and GH3 cells with a high level of MEG3 was confirmed via RT-qPCR.C: Relative β-catenin levels were measured via western blotting.D: Significant negative relationships were found between the expression levels of MEG3 and β-catenin.E: β-catenin levels between GNAS-mutant and wild-type tumors were analyzed using IHC (magnification, ×200).*p < 0.05 and **p < 0.01 show the statistical significance between the two groups as indicated, and "ns" shows no significance.
GNAS mutations on the GHPA phenotype, especially on tumor invasion, and the mechanism involved.
Interestingly, MEG3 was identified as a tumor suppressor that is a downstream target of cAMP [12,37,38].Studies have reported that the level of MEG3 is uniquely high in GHPA but not in NFPAs [39].Thus, we speculate that GNAS mutations suppress the invasiveness of GHPA mainly by activating MEG3.As expected, the high levels of MEG3 were only detected in GHPA-carrying GNAS mutations.MEG3 levels were significantly increased in GH3 cells expressing GNAS mutations compared with GH3 cells expressing wild-type GNAS, suggesting that GNAS mutations inhibit GHPA cell invasion through MEG3 activation.To ascertain the effect of MEG3 on cell invasion, we manipulated MEG3 in GH3 cells.Ectopic expression of MEG3 reduced cell invasion, and conversely, silencing MEG3 enhanced invasiveness.Altogether, our results suggest that MEG3 plays an important role in promoting GHPA invasiveness.
The canonical Wnt/β-catenin signaling pathway is a key regulator of EMT and tumor progression [40].Upon activation of the Wnt pathway, β-catenin accumulates in nuclei and leads to EMT [17].In this study, we showed that GNAS mutations lead to increased MEG3 expression but decreased β-catenin expression.The activation of β-catenin by LiCl enhanced cell invasion, and the inactivation of βcatenin by Dkk1 inhibited cell invasion.Subsequently, elevated MEG3 expression led to the downregulation of βcatenin in GHPA cells.In parallel, the silencing of MEG3 upregulated β-catenin expression, suggesting that MEG3 inhibits the invasiveness of GHPA cells by inactivating the Wnt/β-catenin pathway.However, in this study, the mechanism by which MEG3 regulates β-catenin is unclear.Recent studies have shown that MEG3 inhibits pituitary tumor invasiveness through the MIR-376B-3P/HMGA2 axis [41].Other studies have shown that MEG3 negatively regulates the proliferation, migration, and apoptosis of osteosarcoma through the Wnt/β-catenin pathway by targeting miR-184 [42].MEG3 suppressed liver cancer cell growth by inhibiting β-catenin through the activation of PKM2 and inactivation of PTEN [15].The mechanism by which MEG3 regulates β-catenin-mediated transcriptional activation in GHPA must be investigated.
Anterior pituitary with an epithelial phenotype expresses multiple cadherin proteins, such as E-cadherin, that function in cell attachment [43].EMT is vital for tumor cell invasion and metastasis.The loss of E-cadherin and/or the increase of Ncadherin are hallmarks of EMT.In various tumor types, the Wnt/β-catenin signaling pathway is constitutively active to promote EMT [44].This study uncovered that β-catenin and EMT-related functional proteins are altered by MEG3 in GHPA with GNAS mutations.Accordingly, overexpressing MEG3 in GHPA cells led to the upregulation of E-cadherin but downregulation of N-cadherin and vimentin by altering the transcriptional regulation of β-catenin.
MMPs-important proteolytic enzymes in the degradation of extracellular matrix and basement membrane-are crucial for tumor cell invasion [45].MMP-2 and MMP-9 play vital roles in tumor invasion due to their potent ability to degrade collagen type IV [46].In particular, they play important roles in the invasiveness of GHPA [47].Consistently, in this study, the levels of MMP-2 and MMP-9 decreased in GHPA tumors with GNAS mutations; additionally, the increase in MEG3 expression in GHPA cells resulted in a decrease in the expression of MMP-2 and MMP-9.
Of note, our findings identify a possible mechanism to explain several known GHPAs phenotypes.Our observations that MEG3 activation in somatotroph cells due to an activating GNAS mutation, concomitantly the inactivation of Wnt/β-catenin pathway and inhibition of EMT may explain distinctive somatotroph adenoma features.However, evidence from other studies suggested that somatotroph cAMP has a dual role in promoting growth hormone secretion while causing DNA damage [35].These findings may help explain the smaller, less invasive size of GHPAs containing GNAS mutations, both of which secrete higher levels of growth hormone.Likewise, in our present study, we speculate that cAMP also plays a dual role in GNAS mutation-positive adenomas.The different mechanism is that MEG3 may also play an important role in inhibiting tumor proliferation and invasion in addition to DNA damage.

Conclusions
This study revealed that GNAS mutations are associated with the invasiveness of GHPA tumors, possibly by increasing the level of MEG3.MEG3 upregulation in rat GH3 cells suppress cell invasion by inhibiting Wnt/β-catenin signaling.Silencing MEG3 upregulates β-catenin and enhances EMT.Owing to the lack of growth advantage observed in GHPAs with mutant GNAS, the possible mechanisms in this study were elucidated.Moreover, the findings suggest that MEG3 serves as a biomarker for detecting the GHPA phenotype and inhibition of Wnt/β-catenin signaling can be a useful approach for treating GHPA.

FIGURE 2 .
FIGURE 2. GNAS mutations upregulate MEG3 expression.A: The expression of MEG3 in GHPA and NFPA was quantified via RT-qPCR analysis.B and C: Correlation between MEG3 expression and GNAS mutations was determined via RT-qPCR.D: Correlation between MEG3 expression and percentage of invasive tumors was analyzed.**p < 0.01, ***p < 0.001 show statistical significances between the two groups as indicated.GHPA: growth hormone-secreting pituitary adenoma; NFPA: non-functioning pituitary adenoma; GNAS-MUT: growth hormone-secreting pituitary adenoma possessing GNAS mutations; GNAS-WT: growth hormone-secreting pituitary adenoma possessing wild-type GNAS; MEG3-high and MEG3-low: GHPAs were divided into the MEG3 high expression group and low expression group according to the MEG3 expression level.

FIGURE 5 .
FIGURE 5. MEG3-mediated downregulation of β-catenin inhibits GH3 cell invasion.A: MEG3 was manipulated by expressing or silencing in GH3 cells.The expression of β-catenin was induced by LiCl (20 mM) or repressed by Dkk1 (150 ng/mL) and measured using western blotting.B: Relative cell invasion was quantified by the Transwell assay (magnification, ×200).C: Expression of MMP-2 and MMP-9 was measured using western blotting.*p < 0.05, **p < 0.01 show statistical significance between the two groups as indicated.

FIGURE 7 .
FIGURE 7. MEG3 inhibits GHPA cell invasion in vivo.A: GH3 cells expressing different levels of MEG3 were subcutaneously injected into null mice followed by LiCl treatment.B: Sustained efficiency of MEG3 upregulation was verified by detecting the expression level of MEG3 in the xenograft tumor of each group via RT-qPCR.C, D: Levels of β-catenin, E-cadherin, N-cadherin, MMP-2, and MMP-9 in tumor tissues were quantified via immunohistochemistry (IHC) (magnification, ×200).*p < 0.05, **p < 0.01, and ***p < 0.001 show statistical significance among the three groups as indicated, and "ns" shows no significance.